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Abstract 
Drug metabolism is a detoxification process by which the body converts pharmaceuticals 
into more hydrophilic metabolites. Understanding of the drug metabolism process and 
metabolic profiling plays a vital role in drug development processes by ensuring the safety 
and efficacy of treatments. Cytochromes P450 (CYP) are a superfamily of enzymes that are 
primarily responsible for metabolizing the majority of clinically relevant drugs. In 
preclinical drug development research, there is a constant need for the identification of 
metabolites and their CYP isoenzyme-specific elimination route, as well as possible drug-
drug interactions thereof using high speed in vitro techniques. Miniaturization of the drug 
metabolism assays and related processes could further improve the throughput via 
parallelism and integration of several analytical steps on a single platform, as well as 
reducing the consumption of expensive reagents substantially.  
Micro total analysis systems (µTAS) usually refer to microfabricated devices that 
integrate several analytical unit operations, such as sample preparation, extraction, 
separation, and analysis on a single platform. These µTAS platforms can be either 
continuous-flow microchannel based systems or discrete droplet systems. Digital 
microfluidics (DMF) is one such technology, where sample droplets are manipulated 
individually on an array of electrodes. In DMF, the droplets of hundreds of nanolitres to a 
few microliters of volume can be dispensed, split, mixed, and merged independently via 
programmed and automated voltage application. In this thesis, several DMF-based 
bioanalytical concepts were developed and their feasibility for implementing droplet-scale 
drug metabolism assays was evaluated.  
In the first sub-project, droplet-scale immobilized enzyme reactors were developed by 
immobilizing CYP enzymes on porous polymer monoliths affixed onto a DMF platform. 
Assay incubation at physiological temperature was facilitated by localized heating of the 
DMF platform using integrated inkjet-printed microheaters. For the on-chip detection of 
drug metabolites, a protocol facilitating interfacing of the DMF device with a commercial 
wellplate reader was developed.  
In the second sub-project, the developed DMF platform, featuring the CYP reactors, 
were interfaced with ambient mass spectrometry (MS) via desorption atmospheric pressure 
photoionization (DAPPI). For in situ identification of the drug metabolites by DAPPI-MS, 
the chip design was optimized to be able to control the critical surface sensitive processes, 
such as sample precipitation and subsequent desorption/ionization directly from DMF 
surfaces. In addition, the feasibility of the same platform for a droplet-based liquid-liquid 
extraction of pharmaceuticals was demonstrated. All pharmaceuticals and metabolites 
analyzed could be detected with lower limits of detection in the range of a few picomoles. 
In the third sub-project, DMF droplet manipulation was interfaced with channel 
microfluidics to facilitate more versatile sample preparation such as separation of target 
analytes after the droplet-based enzyme reactions and prior to detection. To support the 
scaling up of the developed technology toward mass manufacturing, the entire device was 
assembled using low-cost inkjet printing and cleanroom-free polymer processing 
techniques. To achieve this interfacing, off-stoichiometric thiol-ene (OSTE) polymers were 
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introduced as a new alternative dielectric material for the coating of inkjet-printed DMF 
electrode arrays, as well as for the integration of the microchannels with a DMF platform. 
In the fourth sub-project, magnetic bead based enzyme immobilization protocol was 
developed to facilitate screening the individual variation of CYP activities in donor-derived 
human liver microsomes (HLM) in droplet-scale. A CYP1A isoenzyme-specific model 
reaction was chosen to assess the inter-individual variation in the activities of this metabolic 
route in the liver microsomes collected from five individuals. The demonstrated protocol 
was shown to be technically feasible for biopsy-scale samples.  
In all, the new droplet-scale concepts developed in this thesis are first-in-their-kind 
examples of droplet-scale drug metabolism assays on DMF platform. The methods 
developed are generally qualitative or semi-quantitative and thus, in their present form, best 
feasible for the preliminary determination of metabolic clearance via CYP or identification 
of the produced metabolites of new drug candidates in vitro. Further development of the 
technology, particularly the enzyme immobilization process and the quantification of the 
produced metabolites, is needed to improve the wider applicability of the assays. It is 
noteworthy however that all of the fabrication processes and interfacing approaches taken 
in this thesis were carried out in regular, cleanroom-free laboratory conditions, which is 
foreseen to significantly improve the adaptability of the technology in any bioanalytical 
laboratories. 
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தினையளவு ப ோதோச ்சிறுபுல் நீரக்ண்ட 
 னையளவு கோட்டும் டித்தோல்  
  
(A droplet as tiny as a millet can project information as big as a palm tree, if examined) 
 
-கபிலர் (Kapilar, 1st century CE) 
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LLE liquid-liquid extraction 
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1 Introduction 
Drug metabolism is the process by which clinically relevant drugs and other xenobiotics are 
transformed into more hydrophilic metabolites by the human body through enzymatic 
reactions taking place primarly in the liver.[1] Understanding the drug-drug interactions 
inside the body is crucial in assessing the safety and efficacy of the drug. Analyzing drug 
elimination (metabolism) from the body is vital in determining the speed and the route of 
drug elimination. Drug efficacy, such as binding to the target receptors, can be predicted 
with the help of computational tools.[2] However, drug metabolism, particularly enzyme 
kinetics, is challenging to predict by computation tools and thus, often requires extensive in 
vitro and in vivo experimentation before the safety and efficacy of the new drug candidate 
can be assured.[3] Additionally, drug metabolism also plays a significant role in the post-
marketing evaluation of the drug safety of critically ill patients by precisely calculating the 
dosage.[4]  
After administration, the disposition of the drug undergoes the following steps inside the 
body: absorption, distribution, metabolism, and elimination, which can simply be referred 
to as ADME. Among these, metabolism is the process by which the drug molecules are 
converted into more water-soluble form primarily by the liver enzymes. In the body, drug 
metabolism is carried out in two phases: (i) modification of the drug molecule into a more 
reactive polar molecule via redox reactions (e.g., dealkylation and hydrolysis) in Phase I 
metabolism, and (ii) further modification of the molecule with additional species, such as 
glucuronic acid, glutathione, etc. via conjugation in Phase II metabolism. Cytochromes 
P450 (CYP) is the superfamily of enzymes that are responsible for the Phase I 
biotransformation of around 70–80% of all pharmaceutical drugs.[5] Thus, understanding 
the disposition of a new drug candidate by the specific CYP enzyme is a crucial step in pre-
clinical drug development.[6] This screening of the isoenzyme specific metabolism of drugs 
is a time-consuming and resource demanding process (Figure 1). From 5,000 to 10,000 
possible candidates, only one new drug gets approved to enter the market and the entire drug 
development process typically takes up to 11–16 years.[7] Therefore, increasing the 
efficiency of the metabolic screening would benefit the pre-clinical drug discovery and 
development process.  
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Figure 1 Drug discovery and development timeline (ADMET-Absorption, Distribution, 
Metabolism, Excretion, Toxicology; PK-pharmacokinetics; PD-pharmacodynamics). 
Reprinted from ref. [7] © 2016 by Matthews et al.; MDPI, CC BY 4.0. 
The miniaturization of analytical systems has been well established in chemical and 
biological research in recent decades to improve the speed of analysis and decrease the cost. 
Via miniaturization, multiple units of chemical analysis, such as sample preparation, 
separation, and detection, can be combined into a single device—a micro total analysis 
system (µTAS).[8] µTAS improves analysis by reducing the sample volume and thus, the 
waste, and by increasing the speed of analysis. Microfluidic (µTAS) systems are extensively 
used in a variety of biological applications, such as enzymatic, immunological, diagnostic, 
and cell-based assays, where the reactions and analyses are carried out in a single 
platform.[9] These microfluidic systems are often called lab-on-a-chip devices nowadays, as 
the entire functional units of laboratory processes can be miniaturized on a single 
microfluidic chip.[10] Using lab-on-a-chip technologies in pre-clinical drug development has 
gained interest in recent years because of their rapidity, cost-effectiveness, and the 
possibility of substantially reducing the consumption of expensive reagents and drugs.[11]  
Digital microfluidics (DMF) is a droplet-based microfluidic technology, where 
individual sample droplets (reactors) are handled via electrowetting-on-a-dielectric 
(EWOD) in an automated fashion and it has been widely used in immunological and 
diagnostic assays over the past decade.[12] The term DMF may sometimes refers to other 
droplet actuation systems, including water-in-oil or oil-in-water emulsion based droplet 
microfluidics. Apart from the EWOD-driven DMF, there are also other approaches to 
manipulate droplets on surfaces via magnetic force,[13] surface acoustic waves,[14] and 
thermocapillary force.[15] However, in the context of this thesis, DMF solely refers to (non-
optical) EWOD-based microdevices.  Unlike other microfluidic systems, DMF does not 
suffer from complex sample loading via tubings and pumps. As a result, there are practically 
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no dead volumes in DMF systems. This is particularly important in the case of expensive 
reagents, drugs and biological samples. Furthermore, DMF allows the usage of complex 
sample matrices, including solid particles and live cells, without any clogging or 
precipitation as in the channels. Owing to its compact size, the system is also portable and 
can be used in point-of-care diagnostic trials.[16] In addition, DMF has been interfaced with 
many analytical methods, such as optical, electrochemical, mass spectrometry, and NMR, 
which allows the user to analyze almost any type of biologically relevant analytes.[17] 
This thesis explores the feasibility of DMF technology to realize drug metabolism 
research in droplet-scale. In the following sections, the theoretical frame and state-of-the-
art DMF technology (Section 1.1), as well as the real-world implications of drug metabolism 
(Section 1.2), will be reviewed. 
1.1 Digital microfluidics (DMF) 
1.1.1 Fundamentals 
Microfluidics refers to the science and manipulation of fluids of picoliter to microliter 
volume inside channels with the dimensions of tens to hundreds of micrometers.[18] A 
microfluidic device in its most common format consists of microchannel(s), where the 
liquids are pumped with the help of spontaneous capillary forces, pressure gradients, or 
electric fields (Figure 2a). However, this study focuses on discrete droplet systems called 
digital microfluidics.[12] Digital microfluidics (DMF) is a droplet-handling technology, 
where discrete droplets of liquid are manipulated on a surface by using an electric field in 
an air or oil filled medium. This is not to be confused with droplet microfluidics, which by 
default, refers to sample droplets manipulated inside a microchannel filled with a continuous 
phase, another immiscible liquid (Figure 2b).[19] In DMF, the sample droplets are moved or 
actuated by selectively wetting the inherently hydrophobic dielectric surface by applying 
voltage, a phenomenon called EWOD.[20–22] By exploiting EWOD, one can perform fluidic 
operations, such as the splitting, dispensing, mixing, rinsing, and merging of droplets by 
applying the voltages selectively (Figure 2c).[23] Like the channel-based microfluidics, DMF 
can also be integrated with many analytical techniques, which makes it a potential 
miniaturized technology for various bioanalytical applications.[17] However, DMF has 
certain benefits that are not present in channel-based microfluidics: (i) no need of auxiliary 
fluidic components, such as pumps, valves, tubing, or external mixers since all of the fluidic 
operations are controlled via electrowetting; (ii) multiple droplets (reactions) can be 
manipulated in parallel on a single device with a compact design; (iii) droplet operations are 
programmable and re-configurable via automation since the devices can use a generic array 
of electrodes; and (iv) samples containing solid particles, beads, and cells can be 
manipulated on DMF without the risk of clogging.  
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Figure 2 (a) Photograph of a simple y-shaped microfluidic channel. Modified and reprinted from 
ref. [24], © 2013 by Orabona et al.; MDPI, CC BY 3.0. (b) Schematic illustration of 
droplet microfluidics. Modified and reprinted with permission from ref. [25], © 2014 
by Elsevier. (c) Droplet operations in digital microfluidics (DMF). Modified and 
reprinted with permission from ref. [12], © 2012 by Annual Reviews. 
In general, DMF devices are categorized between two configurations: one-plate open-
to-air systems[20] and two-plate closed systems.[22] In one-plate devices, the positive 
actuation and ground electrodes are fabricated in parallel (Figure 3a). In two-plate devices, 
the actuation electrodes are at the bottom and a continuous conductive top plate acts as a 
ground electrode (Figure 3b). Two-plate DMF devices are more common in biological 
applications because of their advantages over one-plate configurations in terms of the 
dispensing of droplets from a larger reservoir of electrodes and lower rate of sample 
evaporation during prolonged incubations.  
 
Figure 3 Side-view schematics of: (a) one-plate- and (b) two-plate DMF devices. 
1.1.2 Fabrication and implementation  
A DMF device, in two-plate configuration, consists of four components: substrate, 
electrodes, dielectric layer, and hydrophobic layer (Figure 3b). Proper selection of these 
components is critical, as it determines the complexity and cost of the applicable fabrication 
methods used for the manufacturing of DMF devices. The substrate containing the 
(a) Channel-based microfluidics (c) Digital microfluidics—droplet operations
(b) Droplet microfluidics
VAC
Substrate
Dielectric layer
Actuation electrode
Ground electrode
Hydrophobic coating
(a) One-plate (open) DMF device (b) Two-plate (closed) DMF device
Sample 
droplet Sample 
droplet
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electrodes (bottom plate) is usually fabricated by photolithography and wet etching under 
cleanroom conditions (Figure 4a). These microfabricated bottom plates consist of metal 
electrodes (chromium, gold, copper, or aluminium) patterned onto a glass substrate, which 
serves as actuation electrodes, controlled by external voltage supplies. On the other hand, 
the top plate is usually an ITO-coated glass slide that serves as a continuous ground 
electrode. Both the ITO-coated top plate and dielectric-coated bottom plate are typically 
coated with a sub-micron-thick hydrophobic layer of fluoropolymers, such as Teflon® and 
FluoroPel®, to avoid the sticking of the sample droplets.  
 
Figure 4 Schematics of DMF bottom plate fabrication (examples from literature) by: (a) 
Photolithography and wet etching; reprinted with permission from ref. [26], © 2017 
by IEEE, and (b) Inkjet printing; modified and reprinted with permission from ref. [27], 
© 2014 by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim 
Recently, there have been developments in cleanroom-free techniques to fabricate DMF 
devices, such as microcontact printing,[28] PCB manufacturing,[29] and inkjet printing[30] 
(Figure 4b), which allows for the on-demand customization of electrode arrays for the rapid 
prototyping of new device designs. 
(a) Fabrication of DMF devices by photolithography and wet etching
(b) Fabrication of DMF devices by inkjet printing
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The choice of dielectric material in DMF is crucial, as it affects the driving force (F) 
experienced by a droplet upon actuation, which is given by the following electromechanical 
equation,[12] 
   F= 
𝐿
2
(∑
ε0ε𝑟𝑖,𝑙𝑖𝑞𝑢𝑖𝑑V𝑖,𝑙𝑖𝑞𝑢𝑖𝑑
2 (𝑗2πf)
d𝑖
𝑖 − ∑
ε0ε𝑟𝑖,𝑓𝑖𝑙𝑙𝑒𝑟V𝑖,𝑓𝑖𝑙𝑙𝑒𝑟
2 (𝑗2πf)
d𝑖
𝑖 )            (1) 
where L is side of the cross-sectional area of the droplet, approximated as a square; f is the 
operating frequency; ε0 is the permittivity of free space; εri,liquid, Vi,liquid and εri,filler, Vi,filler are 
the relative permittivity and voltage drop for the liquid and filler fluid portions of the 
electrode, respectively; and di is the thickness of layer i. The subscript i represents one of 
the dielectric, top and bottom hydrophobic, and liquid/filler layers.  From Equation (1), it is 
clear that the driving force of a droplet is dependent on the relative permittivity or dielectric 
constant and the thickness of the dielectric material. Therefore, a material with a high 
dielectric constant that can be coated as a thin film in few-micrometer-thickness is generally 
favored as a dielectric.[31] The most commonly used dielectric material in DMF is Parylene 
C due to its high dielectric constant and defect-free coating by chemical vapor deposition 
(CVD). Due to the relatively high cost of CVD instrumentation, spin-coatable polymers, 
such as SU-8, have also been used as an inexpensive alternative.[32,33] There are also other 
non-cleanroom dielectric materials, such as polyimide or PDMS, that can be coated via 
lamination and spin coating,[34] as well as cyanoethyl pullulan, that can be roll-coated on 
inkjet-printed devices.[35] 
The fluidic operations on DMF are carried out by applying a series of voltages across 
the array of electrodes, and the series can be programmed via automation systems without 
any manual intervention. Recent releases of open source automation systems, such as 
DropBot[36] and OpenDrop,[37] have made automated DMF technology available for 
everyone. 
1.1.3 Detection 
In terms of analyzing the samples, DMF has been integrated with a wide variety of analytical 
systems for both on- and off-line analysis. The most commonly used analytical methods in 
DMF for in situ detection of analytes are optical, electrochemical, and mass spectrometric 
detection. Using optical systems in addition to DMF, fluorescence from immunoassays or 
cells,[38] absorbance from bacterial or algae culture,[39] and chemiluminescence[40] from 
immunoassays have been monitored on-line. To detect electrically active analytes, 
electrochemical (EC) electrodes have been integrated on the DMF substrate along with 
sample actuation electrodes. This allows for the on-line analysis of samples via 
voltammetry,[41] amperometry,[42] and impedance[43] based EC measurements. For non-
targeted analysis and proteomics applications, DMF-based sample preparation has been 
integrated with mass spectrometry (MS).[44] Moreover, samples have been analyzed either 
off-line directly on the surfaces via matrix-assisted laser desorption ionization 
(MALDI)[45,46] and nanostructure-initiator mass spectrometry (NIMS)[46] or on-line via an 
integrated electrospray ionization (ESI) emitter.[47] In rare cases, DMF has also been 
  
 
 
21 
integrated with channel microfluidics for the on-line separation of multiple analytes or 
products prior to analysis,[48,49] and with droplet microfluidics device for single-cell 
assays[50] and yeast cell sorting.[51] There have also been several attempts to integrate DMF 
with surface plasmon resonance (SPR) for imaging DNA hybridization[52] and with NMR 
for the detection of small- and bio-molecules.[53]   
1.1.4 Advantages and current challenges of DMF in chemical biology 
Due to its versatility and reduced consumption of expensive reagents, DMF has been 
extensively used in a variety of applications in chemical biology.[17] These applications 
include, but are not limited to, chemical synthesis,[54,55] enzymatic reactions,[56,57] 
immunoassays,[38,40,58] proteomics,[59,60] biopsy[61,62]-, nucleic acid[63–65]-, and cell[66–68] 
based assays. The advantages of DMF over similar conventional counterpart technology in 
these applications are reviewed in Table 1. 
 
Table 1 Examples of advantages associated with the use of DMF in a variety of applications, 
when compared with conventional methods. Modified and reprinted with permission 
from ref. [69], © 2016 by Elsevier. 
Applications Examples of advantages of using DMF-based methods in lab-on-a-chip 
applications 
Chemical Synthesis –Automation and speed in the synthesis of compounds[54],[55] 
Enzymatic 
Reactions 
–Automation and speed, allowing studies of fast reaction kinetics 
  not achievable before[56] 
−DMF allowed the first step in the development of a biomimetic Golgi[57] 
Immunoassays −Decrease in sample amount (by 100 times)[38] 
−Speed (10 times faster)[38] 
−Portability[58] 
Nucleic Acids −Reduction in sample amount (by ∼5 times)[63] 
−Reduction in time for PCR amplification (by 50%)[64] 
−Improvement in detection limit (by ∼100 times)[65] 
Proteins −Elimination of centrifugation for processing[59] 
−Significant reduction in protein processing analysis (from ∼12 h to  
  30 min)[60] 
Cells, and 
Multicellular 
Organisms 
−Increase in sensitivity (∼20 times)[66] 
−Speed and reduced shear stress in cells, in cell signaling studies[67] 
−Automation[68] 
 
In spite of the aforementioned benefits, there are some challenges in implementing DMF 
in biological applications. These challenges can be both fundamental (such as biofouling 
and sample evaporation) and technical (such as limited throughput, temperature control, and 
DMF-to-world interfacing).  The critical challenge when using DMF for analysis of proteins 
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and other large biomolecules is their non-specific adsorption (i.e., biofouling) onto the 
device surfaces. The commonly used hydrophobic coatings, such as Teflon® or FluoroPel®, 
are somewhat porous and retain proteins and other hydrophobic molecules 
nonspecifically.[70] To avoid the biofouling  and subsequent cross-contamination between 
samples, surfactants such as Pluronics®, are typically added to the sample droplets to 
increase the device’s longevity and reliability.[71] The use of surfactants may however 
impact, for instance, the enzyme activities,[72,73] which should be considered while selecting 
a suitable surfactant for the reaction. Biofouling may also impact the programmed sequences 
(automated assays) if the sample droplet sticks onto an electrode and does not move to the 
next destination. To overcome such issues, image based feedback systems can be used to 
optically sense the position of the stuck droplet, after which a control algorithm is executed 
for re-routing the droplet path until it reaches the destination electrode.[74] Sample 
evaporation is usually more of a challenge on one-plate than two-plate devices, especially 
if the assay protocols are longer than few seconds–minutes. In two-plate devices, the sample 
evaporation becomes significant when the devices are heated to higher temperatures for 
longer periods of time. This can be overcome by either using an oil-medium or replenishing 
the reaction volume with droplets of solvents in air-matrix devices.[75]   
With respect to technical challenges, DMF platforms are usually medium throughput 
systems. The throughput may however be scaled up by increasing the number of DMF 
actuation electrodes, although that simultaneously also increases the lateral dimensions of 
the device. To minimize the number of electrodes needed for actuation of droplets in a 
reaction, more focus is needed in physical design. While designing the electrode arrays, 
efficient routing should be considered between different reactors/modules, and also between 
individual reactors/modules and the input/output reservoirs and thus to be able to perform 
as many as possible parallel operations.[76]   
Even though the use of DMF in bio-chemical and immunological assays has been well-
established, the feasibility of DMF technology for drug discovery and development is 
seldom explored, with a few exceptions. For example, Jabriel et al. explored the feasibility 
of two-plate DMF for high-throughput drug synthesis and screening by demonstrating the 
on-chip parallel synthesis of five different macrocycles[55] and combinatorial synthesis of 
four different peptidomimetics.[77] In another work by Au et al., hepatic organoids were 
cultured to perform drug screenings on a DMF platform.[78] A field that has not attracted 
much interest prior to this thesis work is the implementation of droplet-based drug 
metabolism assays on DMF devices. Drug metabolism per se is one of the corner stones of 
preclinical ADME screening of new drug candidates and could largely benefit from 
miniaturization. Although DMF devices are relatively mature for droplet-based sample 
preparation in general, as reviewed in Table 1, the aforementioned hurdles or development 
needs limit the implementation of enzyme-mediated drug metabolism assays on DMF. First 
critical requirement is the precision of the world-to-DMF interfacing, i.e., the way in which 
the samples are introduced for chemical and biological reactions in a quantitative and 
automated manner.[79,80] A second rarely addressed point of development is DMF-to-world 
interfacing, i.e., the way in which the samples from DMF reactions are processed further if 
the in situ detection is not sufficiently selective.[48,49,80] In case of drug metabolism, it is 
typically desirable to separate the drug metabolites from the parent drug and possible 
cosubstrates prior to their detection. Even though few attempts have been made with respect 
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to sample separation, as mentioned in the previous section (1.1.3), this aspect is not 
thoroughly established likely due to the differences in the applicable microfabrication 
materials and methods. Finally, precise, localized temperature control of DMF devices is 
another critical requirement for enzymatic reactions. Many of the biological applications 
are conducted by placing the chip in a heated incubator.[81] Although there has been some 
development recently with respect to integration of on-chip temperature control using 
heating blocks or commercial heating elements.[79,80] 
1.2 Significance of metabolism to safety and efficacy of drugs 
CYP-mediated drug metabolism studies are important to (i) make predictions of the drug 
clearance in vivo based on metabolic clearance rates determined in vitro (which will be 
discussed in Section 1.2.1) and (ii) evaluate drug clearance in vivo from patient samples, 
such as blood, urine, and tissue biopsy (Section 1.2.2). 
1.2.1 Role in pre-clinical drug development in vitro 
Drug metabolism involves the transformation of drugs, xenobiotics, and other endogenous 
molecules, such as steroids and hormones, by specialized enzyme systems, primarily in the 
liver. Among the drug metabolizing enzymes, the CYP superfamily is responsible for 
metabolism of the majority of drugs and several other xenobiotics. The CYP superfamily 
consists of 18 families (CYP1, 2, etc.) and 44 subfamilies (1A, 2B, etc.).[82] Among those, 
families CYP 1–3 are primarily responsible for the metabolism of the majority of drugs, 
totaling 70–80% of marketed pharmaceuticals,[5,6,83] as well as other drug-like xenobiotics, 
e.g., procarcinogens.[84] To assess the safety and efficacy of new drug candidates, the 
metabolic clearance rate and identification of both the metabolites produced and the CYP 
isoenzymes responsible for their elimination should be carefully studied and examined.[85] 
Although both computational methodologies and nonenzymatic techniques (such as 
electrochemical oxidation or titanium dioxide induced photocatalysis[86]) are available, 
mimicking the selectivity of enzymatic reactions is still challenging to both of these 
methods. Therefore, enzymatic screening of new drug candidates in vitro is vital in the drug 
discovery process. The most commonly used matrices in the assessment of human drug 
metabolism are recombinant CYP enzymes (rCYP), human liver microsomes (HLM), and 
human primary hepatocytes. rCYPs expressed in insect cells are used for the preliminary 
screening of the isoenzymes in charge of the drug candidates’ metabolism.[87] HLMs are 
vesicle artifacts of the endoplasmic reticulum of liver cells prepared from the donor’s liver 
tissues (from deceased donors) for the preliminary in vitro estimation of the metabolic 
clearance.[88] Hepatocytes are also used for the above mentioned in vitro assessments, except 
that these better take into account the full complexity of the cellular scale, including drug 
transport into the cell and metabolite transport out of the cell.[89] In addition to these matrices 
and models, metabolic clearance rates are also assessed from biological fluids (blood, urine) 
during clinical trials and post-marketing studies.[90] 
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1.2.2 Role in drug dosing 
The metabolic activity of some CYP isoenzymes varies between individuals based on 
genetic variations (polymorphisms) and other external factors, such as age, sex, diet, 
medication, disease condition, and exposure to chemicals.[5] This inter-individual variation 
in drug metabolism plays a vital role in the safety and efficacy of treatment, as the drug 
clearance rate is directly correlated with drug concentrations in the blood. Low metabolic 
activity causes increased blood levels, which may lead to toxic or other severe adverse 
effects. However, rapid metabolism causes reduced blood levels, which may lead to 
inefficacy. The most important drug metabolizing CYP enzymes and the primary factors 
affecting their expression in the liver are given in Figure 5.  
 
Figure 5 Fractions of the clinically used drugs metabolized by P450 enzymes and factors 
influencing variability, which are indicated by bold type with possible directions of 
influence indicated (↑, increased activity; ↓, decreased activity; ↑↓, increased and 
decreased activity). Factors of uncertain significance are shown in parentheses. 
Reprinted from ref. [5], © 2013 by Zanger et al.; Elsevier, CC BY-NC-ND 4.0. 
To predict polymorphism based variation in CYP activity, genetic tests exist for specific 
CYP isoenzymes that are known to be polymorphic (for CYP2C9 and 2D6);[91] however, 
these tests are not capable of predicting the variation arising from external factors. 
Therefore, it is more relevant to measure the in vivo CYP activity in the liver, for example 
in the context of biopsying, especially when designing the medical therapy of critically-ill 
patients suffering from cancer, liver diseases, chronic depression, etc. In this study, focus 
was put on the CYP1A1 activity. The activity and regulation of CYP1A1 is responsible for 
the metabolism of several anti-cancer drugs and carcinogenic substances that vary 
significantly based on several non-genetic factors.[92] Environmental exposure to heavy 
metals increases the levels of CYP1A1 due to oxidative stress,[93] while exposure to 
pesticides inhibits the activity of CYP1A1/2.[94] Furthermore, life-style choices, such as 
smoking, is found to affect the CYP1A1 metabolism of anti-cancer drugs, such as erlotinib, 
for which the area under the curve (AUC) is 2.8 times lower than that of non-smokers.[95] 
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Therefore, assessing the CYP activity of individuals requiring life-saving medication would 
radically improve the safety and efficacy of treatment by precision dosing. 
1.2.3 Miniaturization of drug metabolism assays 
Ever since the introduction of the µTAS concept, there has been a constant development of 
new microfluidic technologies for both drug discovery and clinical analysis purposes to 
reduce the consumption of expensive reagents and to spare the limited clinical samples via 
miniaturization. Miniaturized/microfluidic systems provide rapid and parallel analysis with 
improved analytical performance through multiplexing and automation.[96] Thus, 
microfluidics technology has been used for various aspects, such as drug synthesis,[11] drug 
screening,[97] drug metabolism,[98] and drug toxicity screening in vitro,[99] as reviewed in 
Figure 6. Concerning drug metabolism research specifically, the focus has been on the 
implementation of: (i) immobilized enzyme (micro)reactors (IMERs) using recombinant 
enzymes or HLM to assess drug-drug interactions[100] and (ii) organ-on-a-chip models to 
assess drug metabolism on a cell/tissue level.[101] In the IMERs, CYP enzymes are often 
immobilized on channel walls or high-surface-area structures, such as micropillars, 
monoliths, and microbeads[102] and can be further integrated with separation and detection 
units.[103] Enzyme immobilization improves the stability of the enzymes, as well as the 
separation of the reaction solution from the enzymes after the reaction, which facilitates the 
subsequent detection of metabolites.[104,105] There are also other miniaturized systems that 
exist, such as lateral flow paper-based assays, where CYP enzymes are immobilized on 
functionalized paper substrate to assess metabolic clearance[106] and 1134 parallel 
microarrays of nanoliter-scale gel compartments encapsulating CYPs patterned on 
functionalized glass substrates for high throughput CYP assays.[104] Contrary to sub-cellular 
models, which often focus on mechanism-based drug metabolism studies, the organ-on-a-
chip models are most often used for prediction of system level toxicity associated with drugs 
and their metabolites.[107]  
 
Figure 6 Microfluidic methods and their respective applications during the different steps of 
drug discovery. Reprinted with permission from ref. [11], © 2006 by Springer Nature. 
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Although microfluidics in its various forms has been extensively applied to drug 
discovery and development, and DMF has been well-established in various biological 
applications, the potential of DMF in drug metabolism research has not been specifically 
and comprehensively studied before this work. This is likely due to the development needs 
associated with DMF devices, as discussed in chapter 1.1.4, as well as the complexity of the 
CYP system, which includes multiple cofactors, needing to be maintained at physiological 
temperature and having inherently low metabolite yields. In this thesis, CYP metabolism 
assays were implemented on a DMF platform in droplet-scale by thoroughly addressing the 
fundamental and technical challenges assoatiated with the DMF-based enzyme assays.   
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2 Aims of the study 
The overall aim of the study was to implement drug metabolism assays on digital 
microfluidics (DMF) technology in droplet-scale to address the real-world needs of both 
preclinical drug development and the clinical assessment of metabolic clearance from 
patient samples. This was addressed by bridging the technological gaps w.r.t. thermal 
control of the DMF devices, and DMF-to-world interfacing by introducing new materials 
that facilitate sensitive detection of low-yield CYP metabolites by optical and mass 
spectrometric methods and DMF interfacing with channel microfluidics to further improve 
the detection selectivity. Another fundamental aim was to develop low-cost, cleanroom-
free, bench-top fabrication methods and interfaces that can be adapted to routine use in 
standard laboratory conditions and thereby promoting the development of DMF-based 
bioanalytical platforms in general. 
 
More detailed aims include: 
 
 to select and examine DMF dielectric materials suitable for in situ optical and 
mass spectrometry detection of low-yield CYP metabolites on-chip 
 
 to examine the possibility of integrating DMF with channel microfluidics via 
inkjet-printing and using thiol-enes to fabricate the dielectric layer as well as the 
microchannel unit 
 
 to examine the recreation of physiological conditions on-chip by developing a 
microheater-element for localized temperature control to maintain maximum 
enzyme activity 
 
 to examine the feasibility of different solid support materials for CYP 
immobilization for droplet-scale drug metabolism studies on DMF platforms 
 
 to examine the feasibility of fluorescent probes for quantitation of the metabolic 
clearances via different CYP enzymes 
 
 to examine the possibility of ambient MS for in situ identification of the 
metabolite 
 
 to evaluate the feasibility of DMF-based droplet microreactors for the 
determination of patient-to-patient variation in CYP activities 
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3 Materials, instrumentation and standard methods 
This chapter contains the list of chemicals, materials, and instruments used in the study in 
Section 3.1, while protocols of standard methods and off-chip control experiments are 
described in Section 3.2. 
3.1 Chemicals, microfabrication materials and instrumentation 
The chemicals/reagents, solvents and enzymes used in this study are listed in Table 2, 
microfabrication materials in Table 3, and instrumentation and software in Table 4. The 
column “Note” indicates their purposes.  
Table 2 Chemicals and reagents used in the study 
Reagents/materials Manufacturer/supplier Note Publication 
Acetone, Chloroform Sigma-Aldrich, Germany Solvents I, II, IV 
Methanol Sigma-Aldrich, Germany Solvent I-III 
Ethylene glycol, Octonal Sigma-Aldrich, Germany Solvents I, II 
Dimethyl sulfoxide Sigma-Aldrich, Germany Solvent I-IV 
Isopropyl alcohol Sigma-Aldrich, Germany Solvent III 
Trifluoroactic acid Riedel-de Haen, Germany Reagent II 
Milli-Q Water Millipore, France Solvent I-IV 
Magnesium chloride Sigma-Aldrich, Germany Reagent I, II, IV 
Phosphate buffer saline (PBS) Sigma-Aldrich, Germany Buffer I, II, IV 
Ammonium hydroxide Riedel-de Haen, Germany Reagent  
Dipotassium hydrogen phosphate Amresco, OH Buffer salt I, II, IV 
Potassium dihydrogen phosphate Riedel-de Haen, Germany Buffer salt I, II, IV 
Rhodamine B Sigma-Aldrich, Germany Reagent I, II 
Naproxen, Paracetamol, 
Carbamazepine 
Sigma-Aldrich, Germany Drugs II 
Testosterone Sigma-Aldrich, Germany Standard II 
Trizma® base Sigma-Aldrich, Germany Buffer II, IV 
Biotin-PEG4-alkyne Sigma-Aldrich, Germany Reagent I, II 
Alexa Fluor® 488 streptavidin 
conjugate 
Thermo Fisher Scientific, 
MA 
Reagent I, II 
7-ethoxy resorufin Toronto Research 
Chemicals, Canada 
Reagent I, IV 
Dibenzylfluorescein Organix Inc., MA Reagent IV 
Resorufin Sigma-Aldrich, Germany Reagent I, IV 
Recombinant enzymes (CYP1A1, 1A2) Corning, Germany Enzyme 
product 
I, II 
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Human liver microsomes Corning, Germany Enzyme 
product 
IV 
3-Cyano-7-ethoxycoumarin (CEC), 
Cyano-umbelliferone (CHC), 
Coumarin, Umbelliferone, Fluorescein 
Sigma-Aldrich, Germany Reagents IV 
β-nicotinamide adenine dinucleotide 2′-
phosphate reduced tetrasodium salt 
hydrate (NADPH) 
Sigma-Aldrich, Germany Reagent I, II, IV 
Pluronic F-68 Sigma-Aldrich, Germany Reagent I-IV 
Dynabeads® M-280 Streptavidin beads Invitrogen, Norway Magnetic 
beads 
IV 
1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE); 1,2-
dioleoyl-3-trimethylammonium-propane 
(chloride salt) (DOTAP); 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine-N-
(Cap biotinyl) (sodium salt) (biotin-
DOPE); 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (ammonium 
salt) (Liss-Rhod PE) 
Avanti Polar Lipids, AL Lipids I, II, IV 
 
Table 3 Microfabrication materials used in the study 
Materials Manufacturer/supplier Note Publication 
Pentaerythritol tetrakis(3-
mercaptopropionate), > 95% 
(tetrathiol); 1,3,5-triallyl-1,3,5-triazine-
2,4,6(1H,3H,5H)-trione, 98% (triallyl) 
Sigma-Aldrich, Germany Dielectric, 
monolith 
I-IV 
Irgacure® TPO-L BASF, Germany Photoinitiator I-IV 
SU-8 5 Microchem Corp., MA Dielectric I-III 
SU-8 25 Microchem Corp., MA Dielectric III 
SU-8 100 Microchem Corp., MA Master III 
Slygard 184 base elastomer (PDMS) 
and curing agent 
Dow chemical company, 
MI 
Mold III 
Fluorpel® PFC 1604V and PFC 110 
solvent 
Cytonix LLC, MD Hydrophobic 
coating 
I-IV 
Chrome-etchant 3144 Puranal Honeywell International, 
NJ 
Etchant I, II, IV 
AZ 351B resist developer MicroChemicals GmbH, 
Germany 
Developer I, II, IV 
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Novele IJ-220 printing media, Metalon 
JS-B25P silver nanoparticle ink and 
Melton Aqueous Vehicle (solvent) 
NovaCentrix, TX DMF and 
microheater 
III, IV 
AGIC-CP01A4 special coated paper 
and AGIC-AN01 silver nano ink 
AgIC Inc., Japan Microheater I, II 
Sodalime glass coated with chromium 
and Az 1500 
Telic company,CA Bottom plate I, II, IV 
Indium tin oxide coated glass slide Structure Probe Inc., PA Top plate I, II, IV 
Silicon wafers Siegert wafer, Germany Master IV 
Plastic photomasks Micro Lithography 
services, UK 
Patterning I-IV 
ITO-PET film MEMCON Ltd., MI Top plate IV 
 
Table 4 Instruments and softwares used in the study 
Instrumentation/software Manufacturer/supplier Publication 
For microfabrication 
Laurell Spin coater WS-650Mz-23NPPB Laurell Technologies Corporation, PA I-IV 
Dymax 5000-EC series UV flood 
exposure lamp 
Dymax Corporation, CT I-IV 
DropBot DMF automation system, 
controlled by MicroDrop v2.4 software 
Open source (built in-house) I-IV 
FEI Quanta™ FEG scanning electron 
microscope 
FEI company, OG I, IV 
Brother MFC-J5910DW inkjet printer Brother Industries, Ltd., Japan I, II 
AutoCAD 2015 software Autodesk Inc., CA I-IV 
ImageJ image analysis software National Institute of Health, MD I 
For microheater fabrication and characterization 
Epson C88+ inkjet printer Seiko Epson Corporation, Japan II, IV 
CHAL-002 miniature thermocouple  OMEGA Engineering, UK I, IV 
Fluke 289 multimeter Fluke Corp., WA I, IV 
FLIR A325sc IR camera FLIR Systems, WA I 
Retiga 4000R digital microscope camera QImaging, Canada I 
For analytical methods 
Zeiss Axioscope A1 upright 
epifluorescence microscopea 
Zeiss Finland Oy, Finland I, III, IV 
Varioskan LUX multimode well-plate 
reader 
Thermo Fisher Scientific, MA I, IV 
Bruker micrOTOF™ mass spectrometer 
and Compass DataAnalysis 4.0 software 
Bruker Daltonics, Germany II 
Krypton filled PKR 106 V-UV lamp Heraeus Noblelight GmbH, Germany II 
Programmable HV supply Custom built IV 
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PicoScope 2203 AD converter with 
PicoLog recorder 
Pico Technology, UK IV 
a Equipped with HAL 100 (100 W) halogen lamp as excitation source with bandpass excitation (546±6 nm) and 
emission (488-640 nm) filters. 
3.2 Standard methods and protocols 
Biotinylation of recombinant enzymes and human liver microsomes 
 
The biotinylated fusogenic liposomes were prepared as described in reference.[108] The 
lipids DOPE, DOTAP, biotin-DOPE, and Liss-Rhod PE were dissolved in chloroform and 
mixed in the ratio of 1:1:0.1:0.05 (wt-%, 1 mg of total lipid content), while the solvent was 
evaporated to dryness for ca. 2 h in a vacuum desiccator. Next, 1000 µL of PBS buffer was 
added and the re-solubilized lipid mixture was vortexed at RT for 1 h to form multilamellar 
liposomes. The multilamellar liposomes were extruded through a 0.1 µm filter 51 times to 
form biotinylated unilamellar vesicles. The biotinylated unilamellar vesicles were then 
fused with either human recombinant CYP enzymes (rCYP, 1000 pmol/mL) expressed in 
insect cells in Publications I and II or with HLMs (20 mg/mL), the vesicle-like artifacts of 
the ER incorporating membrane-bound CYP (prepared via centrifugation) in Publication IV 
in a volumetric ratio of 1:1, at 37 °C for 15 min. 
 
Control enzyme incubations 
 
The off-chip control incubations in Publication IV were carried out with soluble- and 
immobilized (on magnetic beads) HLM in 100 µL volume in microtubes. The reaction 
solution consisted of the chosen model substrate (Table 5) and cosubstrate (1 mM NADPH) 
in a suitable buffer. The chosen substrates were isoenzyme specific, low, or non-fluorescent 
and known to produce fluorescent metabolites. In the case of soluble enzyme reactions, 
0.8 mg/mL (total protein) of HLMs were used, whereas in immobilized enzyme assays, 
0.25 mg of beads (incorporating the immobilized HLM) were added to the reaction volume. 
The solutions were incubated at 37 °C with a commercial heating block and the detailed 
incubation conditions are given in Table 6. After incubation, the soluble enzyme reactions 
were terminated by adding an appropriate termination solution (Table 6), placing a 
microtube in an ice bath for 15 min, and centrifuging at 16000 g for 10 min. Thereafter, the 
supernatant was collected for further analysis. The immobilized enzyme reactions on beads 
were terminated by separating the magnetic beads with the help of a magnet and collecting 
the supernatant. In both cases, the supernatant was analyzed for fluorescence (originating 
from the metabolites) with a wellplate reader.   
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4 Experimental methods developed in the thesis 
This chapter consists of the experimental methods and protocols developed in this thesis. 
This includes fabrication processes of DMF microchips and microheaters, functionalization 
protocols for the immobilization of CYP enzymes on solid supports, operation protocols of 
on-chip assays, and protocols for integrating DMF devices with microchannel for 
electrophoresis and detection methods for on-chip analysis of metabolites by fluorescence 
or ambient mass spectrometry.  
4.1 Microchip designs, fabrication and operation 
Two types of DMF devices were developed and used in this study: (i) glass-based DMF 
devices for drug metabolism and distribution assays in Publications I, II and IV; and (ii) 
inkjet-printed DMF devices for interfacing with microchannel in Publication III. The 
electrodes and microchannel layouts of the devices were designed using AutoCAD, while 
the devices were fabricated, assembled, and operated in cleanroom-free laboratory 
conditions. Expensive and time-consuming cleanroom fabrication was avoided by using 
commercial glass substrates pre-coated with chromium and AZ resist and inkjet printing for 
fabricating the DMF electrodes and microheaters on the flexible polymer sheets. In all 
subprojects, SU-8 or thiol-ene polymers were used as dielectric materials because of their 
relatively low-cost and simple fabrication via spin-coating and UV curing.  
  
Fabrication of glass-based DMF devices 
 
To fabricate the DMF electrodes, commercial glass substrate (50 mm × 75 mm) bearing 
chromium (100 nm) and AZ 1500 photoresist (530 nm) was patterned with UV exposure 
for 5 s through a plastic mask (commercial mask but designed in-house) bearing the 
electrode patterns. The substrate was then developed with AZ developer (20% in water v/v) 
for 20 s followed by chromium etching with chromium etchant for 45 s. After etching, the 
remaining resist was removed with acetone in an ultrasound bath (5 min). Prior to dielectric 
coating, the contact pads of the electrode arrays on both sides of the bottom plate were 
covered with dicing tape. An 8-µm-thick layer of SU-8 in Publications I and II, or thiol-ene 
in publication IV, were spin-coated and cured by UV exposure to serve as dielectric layers 
(Figure 7). The thiol-ene polymer was prepared from triallyl and tetrathiol monomers mixed 
in a stoichiometric ratio of functional groups. Finally, a sub-micron-thick fluoropolymer 
(1% Fluoropel®) layer was spin-coated onto the dielectric layers and cured by heating. The 
spin-coating, UV/heat curing, and baking (on a hot plate) processes were performed in a 
standard laboratory inside laminar fume hoods to avoid particle contamination. The critical 
fabrication parameters are given in Table 6. The top plate was fabricated by spin-coating 
the fluoropolymer onto an ITO-coated glass plate (25 mm × 75 mm), while the top- and 
bottom plates of the DMF were assembled using two layers of double-sided Scotch® tape 
as spacers, resulting in an inter-plate gap of ~180 µm. 
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Figure 7 Microchip designs used in this study: Top-view photographs of the fully-assembled 
devices, top-view CAD layout of electrodes on the bottom plate, and cross-section 
schematics of the fully-assembled devices.  
Table 6 Critical fabrication parameters of dielectric and hydrophobic coatings. 
Material Purpose 
Spin coating 
parameters 
UV 
curing 
Baking Publication 
SU-8  Dielectric 1600 rpm, 30 s 15 s 
65 °C, 2 min and 
95 °C, 2 mina 
I, II 
Thiol-ene (1:1) Dielectric 2000 rpm, 30 s 2 s N/A IV 
Thiol-ene 
(1:1.25) 
Dielectric 3000 rpm, 30 s 2 s N/A III 
Fluoropel 
Hydrophobic 
coating 
1000 rpm, 30 s N/A 150 °C, 30 min I, II, IV 
1500 rpm, 30 s N/A 150 °C, 30 min III 
a Both pre- and post exposure baking.  
N/A=not applicable; thiol-ene compositions: 1:1=stoichiometric, 1:1.25=25% allyl excess. 
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Fabrication of inkjet-printed DMF devices and microchannel interface 
 
In Publication III, the DMF and MCE electrodes were patterned by printing silver 
nanoparticle ink onto a commercial, porous and flexible polymer substrate (Novele) using 
a commercial Epson inkjet printer. After printing, the substrate was heat-treated at 150 °C 
on a hot plate for 2 min to evaporate the residual solvent from the printed metallic ink. Each 
device pattern was then mounted on a glass plate using adhesive transfer tape, while the 
contact pads were covered with parafilm prior to the spin-coating of the dielectric layer on 
top of the printed electrodes. A 5-µm-thick layer of thiol-ene polymer featuring 25% molar 
excess of allyl (ene) functional groups was spin-coated (Table 6) and cured with masked 
UV exposure in the non-contact mode for 2 s (Figure 8a). The photomask was used to 
expose the MCE electrodes and separated from the polymer layer with 0.15-mm-high 
spacers (Figure 8b). After exposure, the uncured thiol-ene was washed with methanol, 
which resulted in exposing the MCE electrodes. Finally, fluoropolymer was spin-coated and 
cured onto the thiol-ene dielectric by covering the microchannel (bottom) part of the 
substrate with parafilm while coating. The top part of the thiol-ene microchannel was 
fabricated by replica molding as described previously[109] and bonded onto the thiol-ene 
(Figure 8c), though not on the fluoropolymer coated DMF bottom plate, by manual 
lamination at 70 °C and cured under UV for 2 min.[110] The microchannel replication process 
included transferring the channel patterns first from an SU-8 master to a PDMS mold by 
soft lithography and then from PDMS to thiol-ene by UV-replica molding. The detailed 
fabrication protocols of the SU-8 master and PDMS mold are given in Publication III. The 
thiol-ene replica was prepared from a mixture with 25% excess allyl monomer poured onto 
the PDMS mold and cured with UV flood exposure for 5 min. The cured thiol-ene 
microchannel layer was carefully peeled off from the PDMS mold.  
 
Figure 8 (a) Side-view illustration of the thiol-ene coating on printed electrodes and their 
masked exposure. Photographs of (b) the exposed electrodes (dia = 1.6 mm) on thiol-
ene coated bottom plate, and (c) thiol-ene microchannel bonded onto the bottom plate. 
(d) Design of the thiol-ene microchannel unit. 
UV flood exposure
Plastic mask
Cover-slip spacer
(150 µm)
Thiol-ene
Inkjet printed
electrode
DMF bottom
plate
Post-exposure rinsing 
with methanol
Pattern
(a)
Exposed electrode
(b)
BI
BO
SI
SO
Injection 
channel 
(SI-SO)
Separation 
channel 
(BI-BO)
SI-Sample inlet
SO-Sample outlet
BI-Buffer inlet
BO-Buffer outlet
SI–SO = 10 µm
BI–BO = 38 µm
h  w = 25 µm  80 µm
Wax barrier
Copper tape clamped 
to HV supply 
Copper tape 
clamped to ground
(c)
(d)
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The microchannel design features a meandering pattern with dimensions of 38 mm × 
25 µm × 80 µm (length × height × width) and 50 µm (width) tapering at the channel turns 
(Figure 5d). The design also features a double-T junction at the injection cross and Ø2 mm 
circular sample inlets/outlets. Hydrophobic wax barriers were drawn around the inlets of 
the microchannel using a wax pen to avoid leakage of the buffers and contacts between 
inlets under HV application. The contact pads of the MCE electrodes were covered with 
copper tapes before clamping to HV to avoid possible mechanical damage caused by the 
alligator clips. 
An ITO-coated PET film (30 mm × 30 mm) laminated onto a glass slide using adhesive 
transfer tape and coated with fluoropolymer was used as the top plate. The top plate was 
assembled on the bottom plate with the flexible ITO-PET edge resting on top of the 
microchannel inlet (Figure 7). The top plate was grounded by clamping the grounded 
alligator clip to a flexible (conductive) copper tape affixed to the conductive side of the 
ITO-PET (Figure 8c).  
 
Droplet operations and characterization of dielectric properties 
 
The droplet operations on DMF devices were carried out with a DropBot open-source 
automation system[36] using MicroDrop software. Sample droplets were actuated by 
applying 80–140 Vrms at 10 kHz to the bottom plate electrodes, whereas the top plate was 
clamped to the ground. To actuate octanol droplets in drug distribution assays in Publication 
II, a lower frequency of 300 Hz was used. 
To characterize the thiol-ene dielectric in Publication III, unit droplets of water (with 
0.1% m/v Tetronic 90R4 as the surfactant) were actuated back and forth with a normalized 
force of ~25–30 µN/mm with a DropBot controller, as described in the references.[35,111] 
Longevity of the devices were tested by actuating droplets in a circular path with a 
normalized force of 25 µN/mm for 10 minutes, while the peak velocity at each step was 
measured. 
4.2 Microheater fabrication and characterization 
The CYPs are sensitive to changes in temperature and their activities are at a maximum in 
a narrow temperature range close to the physiological temperature.[112] Therefore, the DMF 
device needed to be precisely and locally heated up to ~37 °C. In Publications I, II and IV, 
inkjet printed microheaters were used for the localized heating of DMF devices. Integrated 
localized heaters provide better control over heating time and improved heat transfer 
efficiency compared to heating the entire device inside an incubator, as in cell-based 
applications.[81] All microheaters used in the study were fabricated by inkjet-printing 
conductive silver ink onto flexible substrate. The microheater design bears a meandering 
pattern made of 200-µm-wide-lines covering a 4 mm × 4 mm area (equal to the area of four 
DMF electrodes) in Publications I and II, as well as four such meandering patterns in 
Publication IV to heat four reactions in parallel (Figure 9a). After printing, the heaters were 
heat treated at 150 °C for 2 min on a hot plate. The microheaters were assembled to the 
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bottom side of the DMF bottom plate with the help of a glass support and tape (Figure 9b). 
The temperature distribution across the heated DMF device was visualized with IR 
thermography, which is a fast and high resolution method for mapping the heat distribution 
across microfluidic devices.[113] IR thermographs were taken from the upper surface of the 
top plate. Figure 9c illustrates the local heating of the DMF device with a single heater, 
corresponding to an area of four actuation electrodes (4 mm × 4 mm), where the temperature 
was 36 °C (measured on the top plate), while the rest of the device was close to room 
temperature (RT).  
 
Figure 9 (a) Inkjet-printed microheaters used in this study: Top-view photographs; Insert: 
Magnified CAD layout of meandering heater part. (b) Illustration of DMF device-
microheater assembly. (c, d) Microheater characterization with four-electrode-sized 
water droplet (volume ca. 3 μL) at a heating power of 0.1 W: (c) Infrared (IR) 
thermograph illustrating the temperature distribution on the DMF chip surface (on top-
plate) when heated with microheater (circled, area ca. 4 × 4 mm2), and (d) Fluorescent 
images illustrating the volume loss of a sample droplet due to evaporation upon heating 
to 37 °C at t = 0, 10, and 20 min. b–d are modified and reprinted from ref. [114], 
© 2018 by Sathyanarayanan et al.; Springer nature, CC BY 4.0. 
The microheaters were calibrated by inserting a miniature thermocouple from the side 
of the DMF device into a water droplet (~3 µL = volume covering four actuation electrodes) 
and measuring the temperature of the droplet with the help of a multimeter. In such a way, 
the temperature difference (ΔT) w.r.t. RT was recorded at constant heating power of 0.05, 
(c) Localized heating of DMF device  
4 mm8 mm
t = 0 min t = 20 mint = 10 min
2 mm 2 mm 2 mm
4 mm
4 mm
(a) Printed microheaters used in the study
Publication I & II
Publication IV
Meandering 
heater pattern
Contact pad to power supply
(b) DMF device-microheater assembly 
Top plate
Bottom plate
Printed
microheater
Glass support
Attaching with
tape
Monolith + reaction droplet
(d) Evaporation of sample droplet on DMF device  
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0.1, and 0.15 W. To quantify the loss of a sample volume in a DMF device due to 
evaporation, micrographs of a water droplet containing rhodamine B dye were captured at 
every 1 min interval (Figure 9d) and the area of the droplets were calculated using ImageJ 
and plotted against time to determine the percentage volume loss over time.  
4.3 Enzyme immobilization 
To produce detectable amounts of metabolites, sufficiently high amount of enzymes are 
needed in the metabolism assays. To immobilize such high amounts of CYP enzymes on a 
DMF device, two strategies were used in this study: immobilization of (i) rCYP enzymes 
on porous polymer monoliths in Publications I and II, and (ii) donor HLMs on streptavidin 
coated magnetic beads in Publication IV. 
 
Immobilization of recombinant enzymes on porous polymer monoliths 
 
Porous polymer monoliths bearing excess thiol groups on the surface were fabricated onto 
the DMF bottom plate by UV curing and functionalizing the monoliths via biotin-avidin 
chemistry in situ. The monolith was fabricated out of thiol-ene (50 mol% excess thiol) by 
stirring the monomers along with 0.1% (m/v) photoinitiator and methanol as porogen 
following a previously described protocol.[115] The emulsion (2 µL) was then poured onto 
the hydrophilic spot (diameter = 2 mm) defined on the bottom plate, then the top plate 
attached, and cured with UV (1.5 min). As the methanol evaporated quickly during the UV 
curing, there was no need of an extra step to release the porogens. After curing, the 
monoliths were thoroughly washed with methanol and let dry. Uniform porosity was 
obtained with uniformly packed beads with a diameter of 0.51.0 µm (Figure 10a). The 
monolith was then sequentially functionalized with biotin and green fluorescent 
streptavidin, as described in [92] and with the biotinylated recombinant CYP superosomes 
that also incorporated a red fluorescent stain (Liss-Rhod PE) (Figure 10a). First, the 
monoliths were biotinylated with 2 µL of 1 mM biotin-PEG4-alkyne, cross-linked with 1% 
(v/v) photoinitiator under UV for 1 min. After washing the monoliths with methanol and 
PBS thoroughly, the excess solvent was allowed to dry before incubating with 2 µL of 
0.5 mg/mL streptavidin (Alexa-SA) at RT for 15 min. After incubation, monoliths were 
washed (PBS), followed by incubating with 5 µL of rCYP1A1 (Publication I) or 1A2 
(Publication II) superosome mixture at RT for 15 min. During incubations, small volumes 
of PBS were pipetted intermittently to avoid drying. After functionalization, the monoliths 
were washed with- and stored in PBS until further use.  
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Figure 10 Schematic illustration of the CYP immobilization process via (a) Functionalization of 
porous polymer monolith: (i) SEM image of a thiol-ene monolith; and fluorescent 
images of the monolith functionalized with (ii) Alexa-SA and (iii) rCYP. Revised and 
reprinted from ref. [114], © 2018 by Sathyanarayanan et al.; Springer Nature, CC BY 
4.0 and (b) Functionalization of streptavidin-coated magnetic beads (Dynabeads®) 
with biotinylated-HLMs of donor samples. 
Immobilization of human liver microsomes on magnetic beads 
 
Microbeads are most commonly used in DMF for heterogeneous immunoprecipitation 
assays.[116] In Publication IV, streptavidin coated magnetic beads (Dynabeads®) were 
functionalized with biotinylated HLM (Figure 10b). The biotinylated HLM (preparation in 
Section 3.2) were applied on dry magnetic beads and incubated at RT for 30 min in a rotating 
mixer. After bead functionalization, the supernatant was removed by holding the beads with 
the help of magnets. Thereafter, the beads were washed with PBS 3–4 times and then stored 
in PBS in the refridgerator until further use. 
4.4 Drug metabolism and drug distribution assays 
The activity of the rCYP1A immobilized on monoliths was determined via two assays: (i) 
fluorescence analysis of Ethoxyresorufin-O-deethylase (EROD) assay to assess rCYP1A1 
activity in Publication I, and (ii) mass spectrometric analysis of the metabolite (paracetamol) 
Biotinylation
+
Alexa-SA Biotinylated rCYP
with Lissamine-
Rhodamine B label
Monolith with free surface thiols Monolith functionalized with Alexa-SA Monolith functionalized with rCYP
10 µm
(b) Magnetic bead-based CYP immobilization (Publication IV)
(iii)
1 mm 1 mm
-SH
-SH
-SH
(a) Monolith-based CYP immobilization (Publication I and II)
Biotinylated-HLM 
incorporating CYP
Steptavidin-coated magnetic bead
Magnetic 
bead
Steptavidin
Magnetic bead functionalized with 
CYP-incorporated HLM
(i) (ii)
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produced by phenacetin-O-deethylation via rCYP1A2 in Publication II (Figure 11a). The 
metabolic clearance capacity (via CYP1A1) of the donor HLMs immobilized on magnetic 
beads was assessed based on their EROD activity in Publication IV (Figure 11b). Besides 
enzyme assays, on-chip drug distribution assays that consisted of three-phase liquid-liquid 
extraction (LLE) of selected pharmaceuticals were carried out in Publication II. The DMF 
assay protocols are given in the sections below, while the details of buffers, substrates, and 
metabolite detection wavelengths of drug metabolism assays are given in Table 5. 
 
Figure 11 Schematic illustration of the protocol of on-chip CYP enzyme assays: Determination of 
activity of (a) rCYP enzymes immobilized on monoliths in Publication I and II, and 
(b) donor HLMs immobilized on magnetic beads in Publication IV. 
On-chip drug metabolism assays 
 
The rCYP1A assays with monolith-based IMERs (Publications I and II) were carried out 
with ~3 µL of reaction solution containing substrate and cosubstrate dissolved in buffer 
containing 0.1% (m/v) Pluronic F-68 (reagent details in Table 5). The assays were initiated 
by bringing the reaction droplet to the monolith incorporating the enzymes and incubating 
at ~37 °C for 30 min while applying 0.1 W to the microheater (Figure 11a). To compensate 
the volume loss during incubation (Figure 9d), buffer droplets in size equal to 2 electrodes 
(~1.6 µL) were added to the reaction solution. Incubation was terminated by stopping the 
heating and bringing the droplet away from the monolith area for further analysis. The 
fluorescence of the reaction solution originating from resorufin (metabolite) was monitored 
at ex/em wavelengths of 570/590 nm with a wellplate reader in Publication I, as detailed in 
1. Actuating reaction droplet 
to the monolith area
2. CYP reaction initiated 
(at 37 °C with microheater)
3b. Removal of top plate drying droplet on hydrophilic 
spot for DAPPI-MS analysis (Publication II)
DMF electrode
Reaction 
solution Monolith
Hydrophilic spot
3a. Fluorescence detection with 
wellplate reader (Publication I)
1. Mixing microbeads with 
substrate+co-substrate
2. Incubating reaction solution 
at 37 °C for 30 min with 
microheater under DMF mixing
3. Termination of the reaction by 
separating the beads from the 
reaction solution with a magnet
Magnet
Metabolite
Substrate+
Co-substrate
Microbead
s
(a) Monolith-based drug metabolism assay on DMF device (Publications I and II)
(b) Magnetic bead-based drug metabolism assay on DMF device (Publication IV)
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Section 4.5 under “Fluorescence Detection.” In the case of Publication II, the reaction 
solution was transferred away from the monolith onto a hydrophilic spot and let dry. The 
dried sample spot was analyzed with ambient mass spectrometry (Details in Section 4.5 
under “Mass Spectrometry Detection”).  
The bead-based HLM assays in Publication IV were carried out with four parallel 
reaction solutions, each of ~3 µL droplet volume containing substrate, cosubstrate, and 
HLM incorporated magnetic beads (~1 million) dispersed in a buffer containing 0.1% 
Pluronic F-68 (reagent concentrations in Table 5). The reaction was initiated by applying 
0.2 W to a microheater to incubate the four reaction solutions in parallel at 37 °C for 30 
min. The volume loss of the reaction solution due to evaporation was compensated, as 
mentioned above. The reaction was terminated by stopping the heating and separating the 
beads from the reaction solution with a magnet (Figure 11b). After reaction termination, the 
fluorescence of the reaction droplet was monitored at resorufin ex/em wavelengths. 
 
On-chip drug distribution assays 
 
The feasibility of on-chip LLE for examination of water-octanol distribution of three 
pharmaceuticals (Table 7), along with the internal standard (testosterone) was determined 
using two-step extraction schemes, first from the acidic aqueous phase (0.1% TFA, pH 2, 
acidic functional groups in neutral form) to the organic phase (octanol) and then from the 
organic phase back to the aqueous phase (ammonium hydroxide, pH 12, acidic functional 
groups in ionized form) (Figure 12). These extractions were performed by keeping the 
organic phase (octanol droplet) stationary, while the aqueous droplet was brought in and out 
of it. After the extraction, the aqueous droplet was transferred onto a hydrophilic spot and 
let dry. The dried spot was then analyzed with ambient mass spectrometry.  
Table 7 The chemical structures, monoisotopic masses and chemical properties of the model 
pharmaceuticals used in Publication II. Molecular properties from Chemicalize 
(https://chemicalize.com/) developed by ChemAxon Ltd. (Budapest, Hungary). 
Reprinted from ref. [117], © 2018, Sathyanarayanan et al.; MDPI, CC-BY 4.0. 
Compounds Paracetamol
 
Naproxen
 
Carbamazepine
 
Testosterone
 
Molecular 
formula 
C8H9NO2 C14H14O3 C15H12N2O C19H28O2 
Observed ion 
type 
152.071 
([M+H]+) 
230.095 
(M+•) 
237.102 
([M+H]+) 
289.216 
([M+H]+) 
Monoisotopic 
mass (g/mol) 
151.063 230.094 236.095 288.209 
pKa (acidic) 9.46 4.19 15.96 
n.d. 
(internal qualifier) 
LogD (pH 2) 
LogD (pH 12) 
0.9 
-1.15 
2.98 
-0.54 
2.76 
2.76 
([M+H]+)=protonated ion, (M+•)=radical cation and n.d.=not determined 
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Figure 12 Schematic view of the steps of on-chip drug distribution assay. Revised and reprinted 
from ref. [117], © 2018 by Sathyanarayanan et al.; MDPI, CC BY 4.0. 
4.5 Analytical method interfaces 
Fluorescence detection 
 
For the detection of metabolites produced in on-chip CYP assays in Publications I and IV, 
the DMF devices were interfaced with a wellplate reader, as described in the reference.[118] 
Interfacing with a wellplate reader makes DMF assays compatible with regular laboratory 
instrumentation without the need for custom optical setups. The DMF device was taped on 
top of a well plate lid (96-well) with the analyte droplet(s) aligned along the well(s). The lid 
was then turned and flipped so that the top plate was facing down before placing the chip 
on the wellplate reader tray (Figure 13). Thereafter, the fluorescence was measured with the 
bottom optics of the reader in multi-point mode.[118] However, the fluorescence visualization 
of the functionalized monoliths based on Alexa-SA and lissamine rhodamine B-labelled 
rCYPs in Publication I (Figure 10a) was performed with a regular epifluorescent 
microscope.  
 
Figure 13 Schematic representation of the flip and rotation of the DMF device taped on a 96-
wellplate lid before placing it inside the plate reader tray. Reprinted from the 
ref. [114], © 2018 by Sathyanarayanan et al.; Springer Nature, CC BY 4.0. 
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Mass spectrometry detection 
 
In this study, DMF was interfaced with ambient MS via desorption atmospheric pressure 
photoionization (DAPPI)[119] for the first time. DAPPI is an ambient ionization technique, 
where the dried samples are desorbed with a heated solvent jet and ionized with UV. The 
samples from the drug distribution and metabolism assays in Publication II were transferred 
to the hydrophilic spots on SU-8 dielectric after the reaction. Thereafter, the top-plate was 
removed and the samples were let dry. The hydrophilic spots were made by covering the 
SU-8 with circular dicing tapes (diameter = 1 mm) prior to fluoropolymer coating, while 
the tapes were carefully removed after the baking step (Figure 14a). The dried sample spots 
were then desorbed/ionized from the DMF bottom plate with the DAPPI system and 
analyzed with MS (Figure 14b and c), as described in Publication II. Briefly, the sample 
spots were hit with a jet of chlorobenzene vaporized using a heated nebulizer chip[120] 
(250 °C, 10 µL/min) and introduced along with nitrogen (180 µL/min) as a nebulizer gas. 
The UV lamp was fixed ~10 mm above the sample spot to ionize the desorbed sample 
molecules. The nebulizer chip was fixed at 45° angle w.r.t. DMF plate, while the sample 
spots were kept at ~2 mm from the MS inlet (Figure 14b and c). For spot-to-spot analysis, 
the DMF bottom plate was moved with the help of a xyz positioning stage to align the 
sample spots w.r.t. nebulizer jet and MS inlet (Figure 14d). The extracted ion 
chromatograms (EIC) were taken with an extraction window of ±0.05 m/z and the signal 
quantitated by integrating the peak area (Figure 14e).  
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Figure 14 (a) Schematic view of the fabrication process of digital microfluidic (DMF) bottom 
plate incorporating hydrophilic spots. (b) Photograph of DMF-DAPPI-MS interface. 
Schematic illustration of (c) the process flow of DMF-DAPPI-MS analysis, (d) the 
process of desorption/ionization of samples from the DMF chip surface, and (e) 
integration of the peak area of extracted ion chromatogram (EIC) in DAPPI-MS 
analysis. Modified and reprinted from ref. [117], © 2018 by Sathyanarayanan et al.; 
MDPI, CC BY 4.0. 
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DMF-to-microchannel interface 
 
In Publication III, OSTE was used for implementation of DMF-to-channel microfluidic 
interface. A custom interface for sample delivery from DMF part to the microchannel part 
was developed and a thiol-ene based microchip electrophoresis unit was modularly 
integrated with the DMF bottom plate featuring thiol-ene dielectric. The bonding quality 
was confirmed with an electrophoretic injection and a subsequent fluorescence detection of 
5 µM Oregon green dye. The channel was filled with a borate buffer containing 0.1% (m/v) 
SDS prior to the injection of the sample. For this purpose, the DMF chip, along with the 
pogo pin connector of the DropBot controller, was placed on the microscope sample stage 
(Figure 15a). The sample was loaded with an electric field of 400 V/cm applied over the 
injection channel (20 s) and injected by applying electric fields of 750 V/cm over the 
separation channel. Push back voltages were then applied to the injection inlet and outlet 
(Figure 15b). The fluorescence of the injected Oregon green sample plug was monitored 
perpendicular to the microchannel at the effective separation length of 33 mm and recorded 
with a photomultiplier attached to the microscope and an AD converter. The droplet transfer 
at the digital-to-channel microfluidic interface was visualized with a water droplet 
containing food color in Figure 15c.  
 
Figure 15 (a) Photograph of DMF-electrophoresis set up under the microscope. (b) Tabular 
presentation of electrophoretic voltages used for the injection of 5 µM Oregon green 
fluorescent dye along with the schematics of the microchannel. (c) Still photographs of 
a blue food color droplet (in water) transferred from the DMF part to the microchannel 
part: (i-ii) Actuation of the droplet with DMF towards the microchannel inlet; (iii) 
Filling of the microchannel inlet; and (iv) Filling of the microchannel as soon as the 
inlet is filled. Modified and reprinted from ref. [121], © 2020 by Sathyanarayanan et 
al.; WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim, CC BY 4.0. 
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5 Results and discussion 
5.1 Selection of dielectric material 
In this study, SU-8 (Publications I and II) and thiol-enes (Publications III and IV) were 
selected as the primary dielectric materials based on their: (i) positive dielectric properties 
for prolonged DMF actuation; (ii) low optical background in Publications I and IV; (iii) 
good thermal stability on DAPPI in Publication II; and (iv) compatibility towards 
bonding/integration and low non-specific interactions in Publication III.  
Parylene C is a widely used dielectric material in DMF because it allows for defect-free 
coating by chemical vapor deposition (CVD). However, CVD is a process that requires 
expensive instrumentation.[122] Therefore, spin-coatable polymers, such as SU-8, have been 
used as an alternative dielectric material in DMF applications. SU-8 also enables patterning 
by photolithography for complex fluidic integration (if needed) and has a high dielectric 
constant of 3.5.[123] Thus, SU-8 was chosen as the dielectric layer in this study. Thiol-enes, 
a class of polymers introduced to microfabrication in recent years,[110] also possess similar 
characteristics and advantages as SU-8, and has a dielectric constant of 5.1.[124] The 
feasibility of SU-8 for DMF has been established in the previous literature, whereas thiol-
enes were introduced to DMF as a dielectric for the first time in this study. In this section, 
feasibility of SU-8 and thiol-enes for DMF will be discussed and compared with the view 
to: (i) dielectric properties, (ii) in situ optical detection, (iii) ambient MS detection, and 
(iv) integration with microchannel.  
When spin-coated on a glass substrate, both SU-8 and thiol-ene polymers yielded a 
smooth surface. However, when coated on porous Novele substrate (Figure 16a), SU-8 layer 
was uneven and resulted in a wavy type of surface (Figure 16b). This was likely due to the 
reflow of SU-8 to the pores of the Novele substrate as a result of solvent evaporation during 
the SU-8 soft-bake. In contrast, the solvent-free thiol-ene does not suffer from reflow. As a 
result, smooth planar surfaces were obtained with thiol-ene on Novele substrate (Figure 16c) 
and therefore, it was chosen as dielectric for inkjet-printed devices in Publication III. The 
dielectric performance of both SU-8 and thiol-ene coated devices were comparable to those 
of Parylene C coated devices with typical actuation voltages of 80120 Vrms at 10 kHz. 
Under these driving voltages, SU-8 and thiol-ene coated devices could be used for long term 
(>30 min) continuous actuations for several cycles. The performance of thiol-ene as a 
dielectric layer was evaluated in Publications III (inkjet-printed devices) and IV (glass-
based devices). The droplet velocities on thiol-ene layer under actuation were compared 
with those on Parylene C (Figure 16d). Irrespective of the monomer composition (allyl-rich, 
thiol-rich or stoichiometric), the droplets’ velocities on thiol-ene were similar to those on 
Parylene C.  
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Figure 16 (a) SEM image of Novele substrate. (b,c) 3D profilometer data of the surface of: (b) 
SU-8- and (c) Thiol-ene coating on Novele substrate. (d) Force-velocity plot of 1 µL 
droplets (water containing 0.1% Tetronic) actuated on inkjet-printed DMF devices 
coated with Parylene C and different compositions of thiol-ene. b–d are modified and 
reprinted from ref. [121], © 2020 by Sathyanarayanan et al.; WILEY‐VCH Verlag 
GmbH & Co. KGaA, Weinheim, CC BY 4.0. 
However, one key advantage of thiol-ene as dielectric over SU-8 is its very low 
autofluorescence in the UV-range (Figure 17). This is particularly important for sensitive 
detection of the probe CYP metabolites, some of which fluoresce at near-UV wavelengths. 
Therefore, based on the fluorescence of the CYP probe metabolites used, SU-8 and thiol-
ene were used in Publications I and IV, respectively. 
 
Figure 17 Fluorescence background of SU-8 and thiol-ene coated DMF devices at different 
metabolite detection wavelengths (probe metabolites listed in Table 5). 
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Concerning ambient MS, the most critical properties of the substrate plate are thermal 
and solvent stabilities. In DAPPI, a hot (>200 °C) jet of vaporized chlorobenzene is directed 
at sample spots during desorption/ionization (Figure 14c). Out of the materials tested, thiol-
ene has a lower glass transition temperature (53 ± 2 °C)[125] than that of SU-8 (240 °C).[126] 
Although both polymers show good solvent stability, thiol-ene would not have tolerated 
such a high temperature jet of organic solvent vapor. Therefore, SU-8, which was stable 
under harsh conditions due to its high thermal stability and high degree of cross linking, was 
chosen as the dielectric material for DAPPI-MS analysis in Publication II. No visual damage 
was observed on the SU-8 surface after the normal desorption time of 1–2 minutes. This 
was also evident from the MS spectra, which showed no background ion interference from 
SU-8 (Figure 18a).  
 
Figure 18 (a) Mass spectrum of paracetamol (66 pmol), naproxen (44 pmol), carbamazepine (42 
pmol), and testosterone (70 pmol) dissolved in methanol-water (1:1), deposited onto 
the hydrophilic SU-8 spot, and analyzed by DAPPI-MS. (b) Photograph of rhodamine 
B precipitation pattern on hydrophilic SU-8 spots and on hydrophobic fluoropolymer 
in water and methanol-water. (c,d) EICs of testosterone (internal qualifier, 70 pmol in 
methanol-water) deposited and analyzed from parallel spots (n = 6) by DAPPI-MS: (c) 
on hydrophobic fluoropolymer, and (d) on hydrophilic SU-8 spots. Modified and 
reprinted from ref. [117], © 2018 by Sathyanarayanan et al.; MDPI, CC BY 4.0 
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The efficiency of the desorption process in DAPPI highly depends on the uniformity of 
the sample precipitation pattern, which is largely impacted by the wetting properties of the 
surface.[127] The fluoropolymer surface resulted in tiny, dense precipitation (Figure 18b), 
which was difficult to target with the heated solvent jet and thus, resulted in poor 
repeatability (Figure 18c). Instead, drying the sample (dissolved in aqueous solvent) on 
SU-8 spots resulted in a uniformly spread precipitation pattern (Figure 18b), which 
substantially improved scan-to-scan repeatability (Figure 18d). Additionally, the 
hydrophilic SU-8 spots also helped anchor the sample droplets to the bottom plate while 
removing the top plate for the sample to evaporate prior to DAPPI-MS analysis. 
In principle, both SU-8 and thiol-enes enables the integration of multiple, bonded layers 
via lithographic processing + adhesive bonding and replica molding + bonding, 
respectively. In the case of SU-8, the microchannel layer would have to be spin-coated on 
top of the dielectric layer and adhesively bonded using mask aligner.[128] However, thiol-
enes allowed us to replicate the channel separately and to bond on demand onto the bottom 
plate, which is a less-complicated process, especially with respect to creating sealed 
microchannels.[109] Thus, thiol-ene-on-thiol-ene bonding was used to integrate a 
microchannel on the DMF platform in Publication III. The microchannel integration is 
elaborated in detail in the next section. 
5.2 Digital-to-channel microfluidic interface 
The integration of the DMF platform with microchannel networks was examined in this 
study with a view to carry out sequential fluidic operations on analytical lab-on-a-chip 
platforms. Previous attempts to integrate these two fluidic concepts include, for example, 
an open DMF platform integrated with a PDMS microchannel,[48] a 2-layered 
micromachined glass device featuring DMF and microchannel parts,[49] or two separate 
DMF and microchannel devices interfaced using a capillary.[50] In this study, these two 
systems were integrated on a single substrate/platform, where both droplet actuation and 
channel fluidic operations take place. This was accomplished by: (i) inkjet printing the DMF 
electrodes on flexible substrate; (ii) spin-coating the substrate with thiol-ene dielectric and 
partially with fluoropolymer; and (iii) fabricating and bonding a thiol-ene microchannel 
onto the thiol-ene coated substrate free from fluoropolymer (Figure 19a). As discussed in 
the previous chapter, the inkjet printing of DMF electrodes and the spin-coating of thiol-ene 
dielectric allows for rapid prototyping and the low-cost manufacturing of devices without 
compromising DMF performance. The thiol-ene microchannel can be fabricated by 
cleanroom-free replica molding[109] and bonded to the thiol-ene coated bottom plate free 
from fluoropolymer. In this study, inkjet-printed electrodes also served as MCE electrodes 
thanks to the ability to pattern thiol-ene by masked photolithography to expose the MCE 
electrodes. The thiol-ene microchannel was bonded onto the DMF substrate carefully in a 
way that the electrode feeding the droplet was partially inside the sample inlet of the 
microchannel (Figure 19b). The bonding quality of the thiol-ene microchannel was 
confirmed by electrophoretic injection and the subsequent fluorescence detection of Oregon 
green dye. The electrophoresis performance (peak shape) is very sensitive to any leakage 
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and thus, is a good indicator of defects in the microchannel bonding quality. Figure 19c 
shows the signals from four consecutive injections of Oregon green. The narrow and 
symmetric peaks (peak width at half-height of 1.2 s) and good migration time repeatability 
(3.8% RSD) are evidence that the bonding quality was good.  
 
Figure 19 (a) Schematics of steps involved in the fabrication of integrated DMF-microchannel 
device. (b) Photograph of droplet transfer (food colorant in water) from the DMF part 
to the microchannel inlet and subsequent filling of the microchannel. (c) Fluorescent 
signal (PMT voltage) from n = 4 consecutive injections of 5 µM Oregon green dye with 
migration times on top of the peaks (from injection cross to the point of detection). c is 
modified and reprinted from ref. [121], © 2020 by Sathyanarayanan et al.; WILEY‐
VCH Verlag GmbH & Co. KGaA, Weinheim, CC BY 4.0. 
The bench-top, cleanroom-free approaches used in this DMF-microchannel interface, 
such as the inkjet printing of electrodes, UV patterning of thiol-ene dielectric and 
microchannel layer, as well as the bonding of the microchannel layer, significantly reduces 
the cost. The cost of materials of fully integrated DMF-microchannel device with- and 
without supporting structures (adhesive tapes and support glass plates) are $1.34 and $0.74 
(USD), respectively (detailed cost breakdown can be found in publication IV). Also, these 
approaches can potentially be scaled up to high-volume manufacturing via roll-to-roll 
printing and coating,[35] and roll-to-plate imprinting and sealing.[129]  
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5.3 Development of droplet-scale CYP reactors 
5.3.1 Heating of CYP reactors and evaporation effects 
Most of the DMF-based assays reported in the literature use DMF for only short-term 
operations at RT. However, in this study, the enzyme reactions require elevated 
temperatures and relatively longer incubation times; thus, the longevity of the devices (as 
demonstrated in Chapter 5.1) and evaporation is an issue. Hence, the heating and cooling 
curves, as well as the sample evaporation, were carefully studied in this study. Irrespective 
of the heating power, the temperature of the droplet increases rapidly upon heating for the 
first two minutes and then reaches the plateau at about 10 minutes (Figure 20a). This was 
also true in the case of both single heaters (Publications I and II) and multiple heater patterns 
(Publication IV) (Figure 9a). In Publication IV, four droplets could be evenly and locally 
heated in parallel (Figure 20b). This localized heating is critical in preventing the 
degradation of NADPH (crucial cofactor of CYP reactions) before the reaction. Even though 
the devices used in the study are in a 2-plate DMF configuration, the loss of solvent due to 
evaporation from the gap between the top- and bottom plate is inevitable. CYP enzyme 
reactions are usually carried at the physiological temperature for several minutes[130] and 
thus, evaporation becomes significant in these assays. The volume loss after 10 minutes was 
found to be about 5% at RT and about 12.5% at 37 °C (Figure 20c). As such, the volume 
loss over time was linear (while heating), while the compensating volume of the buffer to 
be added could be somewhat precisely extrapolated based on the evaporation curve 
(Figure 20c).  
 
Figure 20 Microheater characterization with sample droplet of four actuation electrodes (volume 
ca. 3 μL): (a, b) Thermal stabilization curves for the heating and cooling cycles 
obtained from single meander microheater at different heating powers (a), and four 
parallel droplets heated with four microheaters at 0.2 W of total heating power (b). 
(c) Effect of heating and cooling back to room temperature on the volume loss of the 
sample in comparison to the constant decrease in volume at RT. The error bars 
represent the deviation between n = 5 parallel microheaters in a and n = 3 repeated 
experiments in c. a and c were adjusted and reprinted from ref. [114], © 2018 by 
Sathyanarayanan et al.; Springer Nature, CC BY 4.0. 
During DMF assays, appropriate volumes of buffer droplets were added to the reaction 
solution to compensate for the evaporation and thereby, minimize variation in the 
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concentration of substrate and cosubstrate during incubation. Unlike previously used 
heating systems on DMF, such as peltier element,[80] metal heating block,[79] and 
lithographically patterned microheaters,[131,132] the printed microheaters enable on-demand 
customization of assay design by simply redesigning and printing new microheater patterns.  
5.3.2 Selection of enzyme immobilization approaches 
The success and homogeneity of rCYP and HLM immobilization on the monoliths and 
beads could be monitored with the help of the rhodamine tag embedded on the liposomes 
used for the bioinylation step. The rCYPs bound onto the monoliths were quantified 
indirectly based on the EROD activity of rCYP1A1 and found to be ca. 0.9 ± 0.4 fmol 
(n = 10 reactors), assuming that the activity of the immobilized enzymes is similar to that 
of the soluble rCYP1A1. The resulted larger variation of ~44% in the amount of rCYP1A1 
is likely due to the lack of precise control in the surface area of the monoliths, a usual 
downside of the monolith systems used in microfluidics in general. Therefore, the developed 
monolith based enzyme reactor is best suited for qualitative metabolic profiling, such as the 
identification of unknown metabolites by ambient MS, as demonstrated in Publication II. In 
Publication IV, streptavidin-coated magnetic microbeads were functionalized with HLMs, 
as the beads could be separated and retrieved after the assay incubation. This gives the bead-
based assays more flexibility in terms of device reusability over monolith-based assays, 
where the monoliths are permanently fixed onto the device and thus, are single-use. In 
addition, the HLMs have a broad size distribution, ranging from a few-hundreds-of-
nanometers to a few-micrometers. Therefore, b-HLMs might clog the monoliths.  
The activities of the immobilized rCYPs were determined by using ethoxyresorufin O-
dealkylation to resorufin (EROD) via CYP1A1 (Publication I) and that of immobilized 
HLMs by using EROD; CEC dealkylation to CHC via CYP1A2; coumarin 7-hydroxylation 
to umbellifrone via CYP2A6; and dibenzylfluorescein dealkylation to fluorescein via 
CYP3A4 (Publication IV) as the model reactions. In terms of specificity, the CYP1A model 
reactions did not suffer from the interference from any background signals. In Publication 
I, resorufin was detected on-chip with sufficiently good sensitivity (LOD = 36 fmol and 
LOQ = 109 fmol) and linearity (R2 = 0.99; range 0.15–15 pmol) at droplet-scale (Figure 
21a). However, substantial fluorescence backgrounds originated from NADPH and 
substrate at the detection wavelengths of umbelliferone (331/460 nm) and fluorescein 
(495/516 nm), respectively (Figure 21b). These background signals were considered while 
determining the metabolite production of CYP2A6 (umbelliferone) and 3A4 (fluorescein). 
The metabolites were detected on-chip with sufficiently good sensitivity compared to the 
blanks (signals from substrate and cosubstrate) (Table 8). Based on the background signals, 
umbelliferone and fluorescein probe reactions would require the separation of components 
prior to metabolite detection and therefore were not selected as model reactions for further 
CYP assays on-chip. The effect of the number of functionalized beads on metabolite 
production on-chip was evaluated with the CEC probe reaction. This is particularly 
significant because the difference between the signals from the samples cannot be quantified 
if the system gets saturated. The response (metabolite production rate) was found to be 
increasing linearly, along with an increasing number of beads (Figure 21c) and thus, the 
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highest test number of beads (~1 million) was chosen for further on-chip assays. At this 
concentration, the beads were unlikely to cause much impact on the electrowetting 
properties of the aqueous sample droplet.[133] Since resorufin has a lower on-chip detection 
limit than CHC (Table 8), the EROD reaction was chosen for the on-chip diagnostic CYP 
assays for the assessment of metabolic capacity of individual donor samples.  
 
Figure 21 (a) Resorufin calibration curve and schematics of the fluorescence quantification by 
well-plate reader. (b) Selectivity of the metabolite quantitation from model probe 
reactions using immobilized enzymes off-chip; error bars: SD from n = 3 assays for 
CYP1A1 and n = 4 assays for the rest. (c) Effect of bead count on CHC metabolite 
production of pooled HLM on-chip; error bars: SD from n = 3 assays. (d) The 
fluorescence signal of the reaction solutions (positive controls, n = 10, and negative 
controls, n = 4) extracted from the monolith-based rCYP1A1-reactors. (e) Selectivity 
of EROD assay form the bead-based HLM-reactors with pooled HLM (n = 20 donors). 
a and d are modified and reprinted from ref. [114], © 2018 by Sathyanarayanan et al.; 
Springer Nature, CC BY 4.0. 
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Table 8 The limits of detection (LOD) of metabolites of selected on-chip probe reactions 
produced from pooled HLM immobilized on magnetic beads. 
Metabolitea Ex/em (nm) LOD (pmol) Linearity (R2) 
Umbelliferone (CYP2A6) 331/460 1.04 0.992 
3-cyanoumbelliferone (CHC) (CYP1A2) 410/453 0.26 0.9878 
Fluorescein (CYP3A4) 495/516 0.04 0.9987 
Resorufin (CYP1A1) 570/590 0.08 0.9824 
a Detected in respective buffers containing substrate and cosubstrate (concentrations given in Table 5).  
Ex/em = excitation and emission wavelengths. 
 
The EROD reactions on-chip were found to be sensitive enough that the fluorescence 
response of metabolites produced from the assays was higher than those of the control 
experiments (no substrate, enzymes or heating) and blanks (substrate + cosubstrate in 
buffer) (Figure 21d and e). The difference between the average signals from the positive 
and negative controls is statistically significant, as p = 0.001 and 0.026 in monolith- and 
bead-based assays on DMF, respectively. Furthermore, the average resorufin (metabolite) 
production rates of monoliths functionalized with rCYP1A1 and beads functionalized with 
HLM were 20.3 ± 9.0 and 6.8 ± 1.2 fmol/min, respectively.  
5.3.3 Mass spectrometry detection of metabolites  
For metabolite identification purposes, interfacing DMF with ambient MS is by far the most 
straightforward approach; however, it has not been thoroughly examined before this work. 
The integration of a monolith based CYP reactor with DAPPI-MS could be a potential 
alternative approach for preliminary metabolic profiling, i.e., identification of the most 
abundant metabolites of new drug candidates at the early stages of drug discovery. 
Nevertheless, this approach is not readily feasible for the quantitative determination of 
clearance rates similar to that of the fluorescence-based approach. This is due to the 
inherently high variation of signals in DAPPI-MS analysis, which in this study, was 35% 
and 23% RSD for paracetamol (66 pmol; n=5 spots) on SU-8 and PMMA (a common 
substrate for DAPPI-MS)[134] surfaces, respectively. The lower limits of detection (LLOD) 
of the pharmaceuticals (listed in Table 7) were calculated from n=5 replicate spots and 
defined as the lowest concentration at which the analyte gave a detectable signal at all five 
spots. The LLODs of paracetamol, naproxen, and carbamazepine were 1 µg/mL (7 pmol), 
0.25 µg/mL (1 pmol), and 0.5 µg/mL (2 pmol), respectively (tested range: 0.1–10 µg/mL in 
methanol-water 1:1). Thus, the developed method is most feasible for measuring 
pharmaceuticals from biological matrices, such as plasma or urine, where the drug 
concentrations are usually in the range of µg/mL. 
The feasibility of DMF-DAPPI-MS interface for detecting the metabolites of CYP 
reactions was demonstrated with phenacetin O-deethylation assay using rCYP1A2 
immobilized onto the porous polymer monolith. In general, CYP assays are carried out in 
buffers with relatively high salt content such as Tris or phosphate buffers at physiological 
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pH (7.4–7.5). The phosphate buffer is non-volatile and leaves a dense precipitate upon 
evaporation, which makes it inherently unfavorable for any ambient MS analysis. Therefore, 
more volatile Tris was chosen in this study and the signal intensity of paracetamol in Tris 
was observed to be similar to that in methanol-water (1:1) solvent (Figure 22a). The 
metabolite paracetamol produced from the on-chip CYP assays was detected as protonated 
Tris adduct ion [M + Tris + H]+ = 273.199 (Figure 22b). As seen in Figure 22b, the DMF-
DAPPI-MS method is sensitive enough to detect the trace amount of metabolites (few pmol) 
from the on-chip assays, while no metabolite was detected from the negative control 
(without substrate).  
 
Figure 22 (a) Comparison of paracetamol signal intensities in pure solvent (methanol-water 1:1) 
vs. 60 mM Tris buffer (n = 5 samples each). (b) EICs of paracetamol (bold line) 
produced via CYP1A2 mediated phenacetin (bold dotted line) O-dealkylation analyzed 
from the dried precipitate of the enzymatic reaction solution after the on-chip drug 
metabolism assays. Modified and reprinted from ref. [117], © 2018 by 
Sathyanarayanan et al.; MDPI, CC BY 4.0. 
Octanol-water distribution is the usual tool for the assessment of drug solubility and for 
purification of lipophilic compounds from buffer solutions featuring high salt 
concentrations. The DMF-based droplet handling enables small volume sample preparation, 
e.g., liquid-liquid (micro)extraction (LLE), prior to reaction or analysis.[135] Therefore, the 
feasibility of the developed DMF-DAPPI-MS interface was also demonstrated for LLE of 
selected pharmaceuticals via octanol-water distribution. This was carried out by a three-
phase (aqueousorganicaqueous) liquid-liquid extraction (LLE) of naproxen, 
paracetamol, and carbamazepine on DMF. The compounds’ distribution varied based on 
their water solubility and acidity (Table 7). Naproxen being the most acidic (pKa 4.19), 
moderately lipophilic (logD 2.98) at pH 2 and weakly lipophilic (logD -0.54) at pH 12, was 
efficiently extracted from the aqueous to the organic phase in its neutral form and also from 
the organic to the aqueous phase back in ionized form. Whereas, paracetamol, being more 
water soluble (logD 0.91) at pH 2, the extraction from the aqueous to the organic phase was 
not as efficient as naproxen (Figure 23a). Carbamazepine, being weekly acidic (pKa 15.96) 
with lower water solubility (logD 2.76), was not back-extracted from the organic to the final 
aqueous phase, and only paracetamol and naproxen were detected (Figure 23b). 
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Figure 23 (a) Comparison of the repeatability (n = 3 LLE experiments) of intensities of extracted 
paracetamol (initial amount 300 pmol) and naproxen (initial amount 200 pmol) after 
LLE and evaporation of the final aqueous acceptor solution. (b) Mass spectra of the 
final acceptor solution featuring abundant paracetamol and naproxen ions. Modified 
and reprinted from ref. [117], © 2018 by Sathyanarayanan et al.; MDPI, CC BY 4.0. 
5.4 Digital microfluidics for determining personalized drug 
clearance 
The portability, scalability, and versatility of DMF technology has enabled it to be used for 
the rapid on-field diagnosis of infectious diseases[16] and newly born screenings for 
congenital diseases.[136] The key characteristics of DMF that enables these diagnostic assays 
are: (i) very low consumption of reagents and solvents and thus, reduced cost of chemicals, 
(ii) automation of entire assay protocol, which significantly reduces human labor and 
interventions, (iii) portable and scalable as disposable cartridges via mass manufacturing 
process, such as metal printing and roll coating, and (iv) compatibility towards a wide 
variety of biological samples, such as plasma, serum, biopsy tissue, etc.[137] Therefore, DMF 
could be a potential new technology for personalized drug dosing on the basis of the 
patient’s drug clearance capacity since the amount of donor enzymes needed to carry out 
CYP assays are limited, i.e., from liver-biopsies. Genetic CYP diagnostic tests can only be 
used to assess the genotype, but they do not reveal the true expression level or activity of 
the isoenzymes. Therefore, in this study, we examined the feasibility of DMF for measuring 
the true activities (impacted by both genetic and external factors) by screening individual 
and pooled donor liver samples using both DMF-based and conventional (microtube) 
enzyme incubation protocols. For this purpose, EROD was selected as the model reaction 
to assess the CYP1A activity of five individual donor HLMs (donor A–E) and compared 
with that of the artificial population average (pool of 20 donors). The on-chip assay design 
consists of four reaction droplets per donor HLM sample in parallel, as illustrated in Figure 
24a and b.  
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Figure 24  (a) Schematic illustration of the bead-based DMF assay with four parallel reaction 
solutions for the CYP activity screening of donor HLMs. (b) Illustration of the 
separation protocol of beads from a single reaction droplet on the DMF device. 
(c) EROD activity of immobilized HLMs of individual donors (Donor A–E) and 
artificial pool of 20 donors; error bars: SD from n = 4 assays.  
Each reaction droplet was locally heated with a microheater featuring a multi-heater 
pattern, thanks to the region-specific heating of inkjet-printed microheaters (Figure 9b). 
Figure 24c shows the substantial variation in CYP1A activity of donor samples, among 
which activity of donors C and E are statistically significant (p = 0.004 and 0.009, 
respectively) than that of the average population (artificial pool of 20 donors). The detailed 
method validation data can be found in Publication IV. This suggests that the developed 
method is feasible to detect the variation in CYP activities of different individuals at droplet-
scale with reduced enzyme and reagent consumption. In this method, only 15 µg of HLM 
protein per assay is needed (amount needed for the immobilization protocol, not the actual 
amount of immobilized proteins on beads) to functionalize ~1 million beads, the amount 
used in one assay. Thus, the developed DMF-based CYP screening could be performed with 
a small fraction of liver biopsy from patients who undergo biopsy procedure due to critical 
illness. 
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6 Summary and conclusions 
In this thesis, the possibility of carrying out drug metabolism research in droplet-scale using 
DMF technology was studied. This was demonstrated with drug metabolism assays, 
including on-chip metabolite identification as part of pre-clinical drug development and the 
CYP-activity screening of patient samples as part of post-clinical safety treatment (precision 
medicine).  
In Publication I, droplet-scale CYP-IMERs were developed on a DMF platform for the 
on-chip metabolic profiling of drugs. Critical aspects related to CYP assays in droplet-scale 
were addressed: (i) incubation at physiological temperature was carried out using an 
integrated inkjet-printed microheater and (ii) low yield of CYP reactions were addressed by 
implementing porous polymer monoliths to increase the surface area for CYP-
immobilization. The inkjet-printed microheater allowed localized heating of the CYP 
reactors on DMF device and allowed for the customization of assay designs on demand. 
Interfacing with a wellplate reader was straightforward and allowed for the fluorescence 
detection of metabolites without special microscope-PMT systems, which are common in 
microchannel-based devices.  
Mass spectrometry is the gold standard for the non-targeted analysis of molecules and it 
is extensively used in metabolite identification during the drug discovery process. In 
Publication II, the DMF-based CYP reactor was integrated with ambient MS via DAPPI. 
The samples were directly analyzed from the DMF device without any need to integrate 
additional components, such as ESI emitters or capillaries for ionization. The interfacing of 
DMF with DAPPI-MS was possible by using highly stable SU-8 as the dielectric layer, 
which tolerated the high temperature vapor-jet during the desorption/ionization process. 
Also, drying the sample on SU-8 hydrophilic spots played a crucial role in the uniformity 
of sample precipitation, which in turn improved the repeatability of the 
desorption/ionization process. The developed method was sensitive enough to detect few 
pmol of drug metabolites produced from on-chip metabolism assays, as well as the drugs 
extracted from the on-chip distribution assays. DAPPI-MS is inherently a qualitative 
method and therefore, the developed DMF-DAPPI-MS method is not feasible for the 
quantitation of metabolites. Alternatively, this method can be used in the early stages of 
drug development by determining the solubility of drugs via LLE and identification of the 
most abundant metabolites of several isoenzymes via parallel reactions.  
The DMF based sample preparation or assays need interfacing with a microchannel if 
the separation of analytes is required prior to analysis. However, integrating channel 
microfluidics with DMF is not straightforward and requires time-consuming and expensive 
cleanroom manufacturing processes, such as glass micromachining and bonding. In 
Publication III, a digital-to-channel microfluidic interface was achieved by using thiol-ene 
as a novel dielectric material for DMF. Thiol-ene was used both as a dielectric layer and the 
microchannel layer, which facilitated a straightforward thiol-ene-on-thiol-ene bonding. 
Thiol-enes, being solvent-free, enabled a much smoother surface upon coating on the porous 
Novele substrate used for inkjet-printing. Moreover, inkjet-printed electrodes served both 
as DMF actuation electrodes and MCE electrodes exposed on thiol-ene dielectric layer, 
thanks to the UV-patternability of thiol-enes. This interface was developed with careful 
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consideration into the fabrication processes, such as spin-coating, UV-curing and 
patterning, microchannel replication and bonding, which are processes that could potentially 
be transferable to high volume mass-manufacturing. Although the developed interface was 
not applied to drug metabolism studies in the context of this thesis yet, the preliminary 
characterization with fluorescent standards evindenced robust performance of the developed 
digital-to-channel microdevice with a view to rapid online analysis of DMF reactions.  
In Publication IV, the DMF-based CYP assays were used to assess the patient-to-patient 
variation in CYP metabolic capacity. Four parallel assays were carried out and the region-
specific heating of each reaction droplets was made possible with a microheater design 
featuring multiple-meandering patterns. Patient derived HLM samples were immobilized 
on magnetic beads and the functionalized beads were retrieved after the assays, which 
makes the DMF device reusable, unlike fixed monolith-based devices. In this case, thiol-
ene was selected as dielectric material, which allowed the optical detection of metabolites 
also in the UV range, at which SU-8 gives substantial fluorescence background due to auto-
fluorescence. The amount of sample needed was 15 µg of total protein per assay, suggesting 
that this method is feasible for assessing the CYP activity using biopsy samples. The 
developed method was sensitive enough to determine the variation in individuals’ CYP 
activities. With the automation and portability of DMF technology, this method could 
potentially be adapted in near-clinical laboratories with a view towards precision medicine 
for the screening of CYP activities for critically-ill patients. 
In conclusion, the novel contributions arising from this work included several 
improvements in the cleanroom-free microfabrication and interfacing of DMF devices, and 
introducing DMF to a completely new application field focusing on the drug metabolism in 
human. Although high-throughput requirements were specifically not addressed in this 
study, the developed DMF-based systems are the initial steps towards the conceptualization 
of droplet-scale drug metabolism research. This thesis addressed the technological 
challenges in bringing down the drug metabolism research to droplet-scale by: (i) selecting 
DMF dielectric materials that are compatible with different detection methods to analyze 
lower amounts of metabolites, (ii) immobilization of enzymes (membrane proteins) on solid 
supports to increase the yield of the reactions on DMF, (iii) integrating on-demand 
microheaters for the localized heating of enzymatic reaction, and (iv) fabricating and 
interfacing devices with cleanroom-free, inexpensive, bench-top techniques to make them 
adaptable in common laboratory conditions. The developed droplet-scale systems can 
potentially contribute to pre-clinical drug development by significantly reducing the time, 
cost, and usage/wastage of expensive chemicals. In addition, the droplet-scale CYP activity 
screening can potentially be implemented as a diagnostic tool for the precision dosing of 
life-saving medicines. The DMF-based methods developed in this thesis in their present 
form are qualitative or semi-quantitative and therefore, could not readily be used for the 
prediction of kinetic parameters, such as intrinsic clearance (CLint) or IC50 inhibition 
constant. For that to be achieved, more focus in the future is needed on improving 
quantification limits, as well as the repeatability of the immobilization process w.r.t. the 
amount of immobilized enzymes per unit surface area. Also, the throughput of the current 
systems should be addressed to be on par with that of the state-of-the-art wellplate 
technologies that are routinely used in modern drug discovery.  
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